Revolutionizing Cancer Treatment: ImmunoAct Scales Up Gene Therapy
Published on: Nov. 5, 2025, 9:41 p.m. | Source: Devdiscourse
ImmunoAct, backed by government funding, is advancing CAR-T cell therapy to make cancer treatment more accessible. Their product, NexCAR19, uses patients' immune systems to fight cancer. With support from IIT Bombay and BIRAC, they aim to scale production while ensuring affordability and efficacy.
